within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EJ04_Momelotinib;

model Momelotinib
  extends Pharmacolibrary.Drugs.ATC.L.L01EJ04;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01EJ04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Momelotinib is an orally bioavailable, small molecule inhibitor of Janus kinase 1 and 2 (JAK1/2) and activin A receptor type I (ACVR1). It is primarily used for the treatment of myelofibrosis, a type of myeloproliferative neoplasm, and is approved for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients with myelofibrosis following oral administration.</p><h4>References</h4><ol><li><p>Xin, Y, et al., &amp; Silverman, JA (2018). Pharmacokinetics and Safety of Momelotinib in Subjects With Hepatic or Renal Impairment. <i>Journal of clinical pharmacology</i> 58(4) 522–532. DOI:<a href=\"https://doi.org/10.1002/jcph.1050\">10.1002/jcph.1050</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29283448/\">https://pubmed.ncbi.nlm.nih.gov/29283448</a></p></li><li><p>Zheng, J, et al., &amp; Silverman, JA (2018). Pharmacokinetics and Disposition of Momelotinib Revealed a Disproportionate Human Metabolite-Resolution for Clinical Development. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 46(3) 237–247. DOI:<a href=\"https://doi.org/10.1124/dmd.117.078899\">10.1124/dmd.117.078899</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29311136/\">https://pubmed.ncbi.nlm.nih.gov/29311136</a></p></li><li><p>Padda, SK, et al., &amp; Wakelee, HA (2022). A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer. <i>Cancer chemotherapy and pharmacology</i> 89(1) 105–115. DOI:<a href=\"https://doi.org/10.1007/s00280-021-04369-0\">10.1007/s00280-021-04369-0</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34773474/\">https://pubmed.ncbi.nlm.nih.gov/34773474</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Momelotinib;
